Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978407807> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W1978407807 endingPage "195" @default.
- W1978407807 startingPage "177" @default.
- W1978407807 abstract "The Metabolic Syndrome is commonly associated with an atherogenic dyslipidemia which accounts for a high risk of atherothrombosis and cardiovascular events. The fundamental defect of patients with the Metabolic Syndrome is the resistance to insulin action which is involved in the appearance of a combined dyslipidemia -i.e. hypertriglyceridemia, low HDL cholesterol, preponderance of small dense LDL particles and post-prandial lipidemia- owing to a reduced suppression of lipolysis in adipose tissue which leads to higher flux of free fatty acids to liver and increased synthesis and secretion of VLDL particles. Beyond the primary management which involves lifestyle intervention, patients with the Metabolic Syndrome could be treated with different therapeutic strategies to reduce cardiovascular risk. The main therapeutic option is statin therapy which provides effective decrease of LDL cholesterol levels and is shown effective in the prevention of coronary artery events, even though controlled studies are available only for few molecules. In turn, controlled trials -such as BIP, VA-HIT and FIELD- have proposed a possible benefit from fibrate administration in normalizing lipid profile and decrease insulin resistance in patients with the Metabolic Syndrome which exhibit low HDL cholesterol and hypertriglyceridemia. Other lipid modifying strategies based on nicotinic acid or ezetimibe have recently proposed as effective in the Metabolic Syndrome on the basis of preliminary results and could be future options. Finally, the simultaneous use of different drugs could provide benefits, avoiding inappropriate combinations due to the potential hazard of adverse drug interaction. The present review extensively examines the most recent results in the field of treatment of dyslipidemia in patients with the Metabolic Syndrome, starting from the trials with statin therapy. We consider also the role of drugs which regulate serum lipids by different mechanisms, such as fibrates, ezetimibe, nicotinic acid and omega3 fatty acids, on the basis of the evidences of effectiveness and safety. Finally, we take into account the therapeutic efficacy of new drugs, such as glitazones and rimonabant, whose main target is to improve the insulin sensitivity. Keywords: Atherogenic dyslipidemia, metabolic syndrome, statins, fibrates, ezetimibe, nicotinic acid" @default.
- W1978407807 created "2016-06-24" @default.
- W1978407807 creator A5041207535 @default.
- W1978407807 creator A5090558283 @default.
- W1978407807 date "2007-09-01" @default.
- W1978407807 modified "2023-09-26" @default.
- W1978407807 title "The Atherogenic Dyslipidemia of Metabolic Syndrome- Are there New Effective Therapeutic Options Beyond Statins?" @default.
- W1978407807 doi "https://doi.org/10.2174/157488507781695676" @default.
- W1978407807 hasPublicationYear "2007" @default.
- W1978407807 type Work @default.
- W1978407807 sameAs 1978407807 @default.
- W1978407807 citedByCount "0" @default.
- W1978407807 crossrefType "journal-article" @default.
- W1978407807 hasAuthorship W1978407807A5041207535 @default.
- W1978407807 hasAuthorship W1978407807A5090558283 @default.
- W1978407807 hasConcept C126322002 @default.
- W1978407807 hasConcept C134018914 @default.
- W1978407807 hasConcept C2776839432 @default.
- W1978407807 hasConcept C2776919658 @default.
- W1978407807 hasConcept C2776933373 @default.
- W1978407807 hasConcept C2777391703 @default.
- W1978407807 hasConcept C2778096610 @default.
- W1978407807 hasConcept C2778163477 @default.
- W1978407807 hasConcept C2778657065 @default.
- W1978407807 hasConcept C2778913445 @default.
- W1978407807 hasConcept C2780092750 @default.
- W1978407807 hasConcept C2780578515 @default.
- W1978407807 hasConcept C555293320 @default.
- W1978407807 hasConcept C71924100 @default.
- W1978407807 hasConcept C98274493 @default.
- W1978407807 hasConceptScore W1978407807C126322002 @default.
- W1978407807 hasConceptScore W1978407807C134018914 @default.
- W1978407807 hasConceptScore W1978407807C2776839432 @default.
- W1978407807 hasConceptScore W1978407807C2776919658 @default.
- W1978407807 hasConceptScore W1978407807C2776933373 @default.
- W1978407807 hasConceptScore W1978407807C2777391703 @default.
- W1978407807 hasConceptScore W1978407807C2778096610 @default.
- W1978407807 hasConceptScore W1978407807C2778163477 @default.
- W1978407807 hasConceptScore W1978407807C2778657065 @default.
- W1978407807 hasConceptScore W1978407807C2778913445 @default.
- W1978407807 hasConceptScore W1978407807C2780092750 @default.
- W1978407807 hasConceptScore W1978407807C2780578515 @default.
- W1978407807 hasConceptScore W1978407807C555293320 @default.
- W1978407807 hasConceptScore W1978407807C71924100 @default.
- W1978407807 hasConceptScore W1978407807C98274493 @default.
- W1978407807 hasIssue "3" @default.
- W1978407807 hasLocation W19784078071 @default.
- W1978407807 hasOpenAccess W1978407807 @default.
- W1978407807 hasPrimaryLocation W19784078071 @default.
- W1978407807 hasRelatedWork W148721238 @default.
- W1978407807 hasRelatedWork W1966677182 @default.
- W1978407807 hasRelatedWork W1988342110 @default.
- W1978407807 hasRelatedWork W2017928966 @default.
- W1978407807 hasRelatedWork W2069491405 @default.
- W1978407807 hasRelatedWork W2079322705 @default.
- W1978407807 hasRelatedWork W2474843915 @default.
- W1978407807 hasRelatedWork W2780927367 @default.
- W1978407807 hasRelatedWork W3034636523 @default.
- W1978407807 hasRelatedWork W2524048909 @default.
- W1978407807 hasVolume "2" @default.
- W1978407807 isParatext "false" @default.
- W1978407807 isRetracted "false" @default.
- W1978407807 magId "1978407807" @default.
- W1978407807 workType "article" @default.